The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application

被引:567
作者
Wu, Jun [1 ]
机构
[1] Beckman Res Inst City Hope, Ctr Comparat Med, 1500 East Duarte Rd, Duarte, CA 91010 USA
关键词
EPR effect; nanomedicine; drug delivery; arterial infusion; canine cancer; TUMOR BLOOD-FLOW; PEGYLATED-LIPOSOMAL DOXORUBICIN; POSITRON-EMISSION-TOMOGRAPHY; SOLID TUMORS; VASCULAR-PERMEABILITY; CANCER-CHEMOTHERAPY; MACROMOLECULAR THERAPEUTICS; ANGIOTENSIN-II; DRUG-DELIVERY; IN-VITRO;
D O I
10.3390/jpm11080771
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Chemotherapy for human solid tumors in clinical practice is far from satisfactory. Despite the discovery and synthesis of hundreds of thousands of anticancer compounds targeting various crucial units in cancer cell proliferation and metabolism, the fundamental problem is the lack of targeting delivery of these compounds selectively into solid tumor tissue to maintain an effective concentration level for a certain length of time for drug-tumor interaction to execute anticancer activities. The enhanced permeability and retention effect (EPR effect) describes a universal pathophysiological phenomenon and mechanism in which macromolecular compounds such as albumin and other polymer-conjugated drugs beyond certain sizes (above 40 kDa) can progressively accumulate in the tumor vascularized area and thus achieve targeting delivery and retention of anticancer compounds into solid tumor tissue. Targeting therapy via the EPR effect in clinical practice is not always successful since the strength of the EPR effect varies depending on the type and location of tumors, status of blood perfusion in tumors, and the physical-chemical properties of macromolecular anticancer agents. This review highlights the significance of the concept and mechanism of the EPR effect and discusses methods for better utilizing the EPR effect in developing smarter macromolecular nanomedicine to achieve a satisfactory outcome in clinical applications.
引用
收藏
页数:8
相关论文
共 56 条
[1]   Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts [J].
Baker, Jennifer H. E. ;
Lindquist, Kirstin E. ;
Huxham, LynseyA. ;
Kyle, Alastair H. ;
Sy, Jonathan T. ;
Minchinton, Andrew I. .
CLINICAL CANCER RESEARCH, 2008, 14 (07) :2171-2179
[2]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[3]   Principles of nanoparticle design for overcoming biological barriers to drug delivery [J].
Blanco, Elvin ;
Shen, Haifa ;
Ferrari, Mauro .
NATURE BIOTECHNOLOGY, 2015, 33 (09) :941-951
[4]  
Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/NNANO.2012.45, 10.1038/nnano.2012.45]
[5]   To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? [J].
Danhier, F. .
JOURNAL OF CONTROLLED RELEASE, 2016, 244 :108-121
[6]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[7]   HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases [J].
Dozono, Haruhiko ;
Yanazume, Shintaro ;
Nakamura, Hideaki ;
Etrych, Tomas ;
Chytil, Petr ;
Ulbrich, Karel ;
Fang, Jun ;
Arimura, Takeshi ;
Douchi, Tsutomu ;
Kobayashi, Hiroaki ;
Ikoma, Michiaki ;
Maeda, Hiroshi .
TARGETED ONCOLOGY, 2016, 11 (01) :101-106
[8]  
Duncan, 1999, Pharm Sci Technol Today, V2, P441, DOI 10.1016/S1461-5347(99)00211-4
[9]  
DVORAK HF, 1988, AM J PATHOL, V133, P95
[10]   Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers [J].
Fang, Jun ;
Islam, Waliul ;
Maeda, Hiroshi .
ADVANCED DRUG DELIVERY REVIEWS, 2020, 157 :142-160